Viral disease prevention after hematopoietic cell transplantation.

摘要

Hematopoietic cell transplant (HCT) candidates should be tested for the presence of serum anti-CMV IgG Abs before transplantation to determine their risk for primary CMV infection and reactivation after HCT (AII). CMV is shed intermittently from the oropharynx and from the genitourinary tract of both immunocompetent and immunosup-pressed subjects. There are no data showing that avoiding these body fluids is feasible or effective in preventing the acquisition of CMV in CMV-seronegative HCT recipients. As CMV-seronegative pregnant healthcare workers (HCWs) may be at risk for contracting CMV from these and other patients, standard universal precautions should be used in these situations.